Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $97

Benzinga · 2d ago
Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $90 to $97.